<DOC>
	<DOCNO>NCT00810589</DOCNO>
	<brief_summary>Clinical pharmacology trial investigate insulin detemir subject type 1 diabetes show prolonged reproducible action profile insulin detemir compare NPH insulin insulin glargine . Duration action insulin detemir report 24 hours.9,10,11 It , however , propose mean duration action underestimate glucose clamp last 24 hour . This duration action longer 24 hour individual clamp set 24 hour mean calculation , whereas short duration action individual clamp set true value . It show clinical pharmacology trial NPL insulin action profile comparable NPH insulin subject type 1 diabetes . , However , direct comparison pharmacodynamic property insulin detemir NPL insulin perform date . To get insight pharmacodynamic property insulin detemir compare NPL insulin , trial design compare pharmacodynamics general duration action particular insulin detemir NPL insulin subject type 1 diabetes .</brief_summary>
	<brief_title>A Randomised , Single Centre , Double-Blind , Two-Period Crossover , Glucose Clamp Trial</brief_title>
	<detailed_description>Primary objective : The primary objective compare pharmacodynamic response insulin detemir NPL insulin respect duration action 32-hour euglycaemic glucose clamp experiment follow single dose administration subject type 1 diabetes . Secondary objective : The secondary objective : - additionally characterise pharmacodynamic profile insulin detemir NPL insulin 32-hour euglycaemic glucose clamp experiment follow single dose administration subject type 1 diabetes . - characterise pharmacokinetic profile insulin detemir NPL insulin follow single dose administration subject type 1 diabetes . - ass safety tolerability insulin detemir NPL insulin follow single dose administration subject type 1 diabetes . Trial design : This randomise , single centre , double-blind , two-period crossover trial . Each subject randomly allocate two single dose administration two separate dose visit . Trial population : Thirty ( 30 ) male female subject type 1 diabetes [ age 18-65 year ( incl . ) body mass index 18.0 32.0 kg/m2 ( incl . ) ] randomise trial . Assessments : Pharmacodynamics : The glucose infusion rate plasma glucose concentration measure euglycaemic glucose clamp run 32 hour dose . Pharmacokinetics : Serum concentration insulin detemir insulin lispro measure frequently first 32 hour dose . Safety : Adverse event , laboratory safety variable ( haematology , biochemistry , urinalysis ) , physical examination , vital sign hypoglycaemic episode . Trial product : - Insulin detemir ( Levemir® Novo Nordisk ) , 100 U/mL 3 mL Penfill® cartridges - Insulin lispro protamine suspension ( Humalog® NPL , Eli Lilly ) , 100 U/mL 3 mL cartridge</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>1 . Informed consent obtain trialrelated activity . 2 . Diagnosed type 1 diabetes treat insulin 3 . Male female subject 18 65 year age 4 . Body mass index 18.0 32.0 kg/m2 5 . HbA1c ( glycosylated haemoglobin A1c ) ≤ 11 % 6 . Fasting Cpeptide ≤ 0.05 nmol/L 7 . Treatment intensified insulin therapy continuous subcutaneous human insulin insulin analogue infusion ( CSII ) ] least 3 month . Exclusion criteria 1 . Known suspect allergy trial product relate product , 2 . Previous participation ( randomise ) trial . 3 . The receipt investigational product within 3 month prior 4 . Clinically significant abnormal haematology biochemistry screen test 5 . Subject know hepatitis carrier Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody , positive result test HIV antibody . 6 . Supine blood pressure screening ( 5 min supine position ) ≥ 180 mmHg systolic and/or ≥ 100 mmHg diastolic . This exclusion criterion also pertain subject antihypertensive . 7 . Clinically significant abnormal ECG screen 8 . Subject donate blood excess 500 mL within 9 week precede screening . 9 . Significant history alcoholism drug/chemical abuse 10 . Smoker 11 . Subject mental incapacity language barrier 12 . Surgery trauma significant blood loss within 9 week precede screening . 13 . Subject history presence cancer 14 . History illness disease , opinion Investigator might confound result trial pose additional risk administer trial product subject . 15 . Current systemic treatment drug could interfere glucose metabolism [ systemic corticoid monoamine oxidase ( MAO ) inhibitor ] and/or pharmacokinetics . 16 . Subject proliferative retinopathy maculopathy and/or severe neuropathy ( particular autonomic neuropathy ) 17 . Any condition would interfere trial participation evaluation result , judge Investigator and/or sponsor . 18 . Female childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>